Orexo grants ex-US rights for Zubsolv to Mundipharma

Swedish drug developer Orexo (STO: ORX) has granted Mundipharma’s network of independent associated companies´ exclusive global (ex-US) rights to Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII), for treatment of opioid dependence.

Under the terms of the agreement Orexo receives an upfront payment of 7 million euros ($7.8 million). Pending marketing authorizations and commercial milestones Orexo is also entitled to receive further milestone payments and up to low double digit royalties on future net sales. Orexo will also be compensated for specific expenses related to the work required to prepare Zubsolv for markets outside the US.

In addition, the launch of Zubsolv outside the USA will increase production volumes and over time this could considerably improve Orexo’s gross margin.